NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

RecruitingPhase 1

Sponsor: Hemab ApS

Conditions: Healthy Adult Participants

Interventions: HMB-003, Placebo

Countries: United States

The purposes of this clinical study are 1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.

Eligibility overview

Sex: ALL

Age: 18 Years to 50 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.

Exclusion Criteria:

* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \<6 weeks postpartum.
* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.

Locations (1)

San Antonio, Texas, United States